Healthcare, Pharma & Life Sciences

Boston Globe Media, Tufts Health Plan Launch Season 6 of 'Turning Points'

Boston – September 30, 2026 -- Boston Globe Media and Tufts Health Plan have renewed their branded content partnership for a sixth season of "Turning Points: Navigating Mental Health," a five-episode podcast series debuting new installments every Wednesday starting October 7, 2026.

Studio/B produces the series as branded content separate from newsroom operations

The podcast is created by Boston Globe Media's branded content division, Studio/B, in collaboration with Tufts Health Plan, a Point32Health company. The Boston Globe's news and editorial departments have no role in the production, the companies confirmed.

Season six tackles parenting, loss and news-cycle anxiety

The new season addresses parenting in the age of social media, starting over after loss, and managing mental health amid a constant news cycle. Clinical social worker Frantzes Lys returns as host, interviewing guests about personal mental health turning points.

HCTI Signs MOU for 70% Stake in Humanoid Nursing Robot JV

Pleasanton, Calif. – – September 30, 2026 -- Healthcare Triangle, Inc. (Nasdaq: HCTI) has signed a Memorandum of Understanding with Malaysia's AI World Sdn. Bhd. to form a joint venture deploying AI-enabled humanoid nursing robots across North American hospitals, with HCTI taking a 70% ownership stake against AI World's 30%.

Joint venture targets toileting and hygiene care, among the most physically demanding nursing tasks

The proposed venture would hold intellectual property and distribution rights for the robots in North America. The machines are designed to assist with patient toileting and related cleaning and hygiene work under clinical supervision, tasks HCTI says are both physically taxing for staff and sensitive for patients.

Upsher-Smith Launches Generic Fluvoxamine ER, Targets $44.6M US Market

Image
Upsher-Smith Launches Generic Fluvoxamine ER, Targets $44.6M US Market

Maple Grove, Minn. – September 30, 2026 -- Upsher-Smith Laboratories, LLC has launched Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths, entering a U.S. market valued at approximately $44.6 million according to IQVIA data covering August 2025 through July 2026.

Upsher-Smith secures AB-rated status against branded Luvox CR

The product carries a Therapeutic Equivalence (TE) code of AB, with Luvox CR designated as the Reference Listed Drug. The AB rating allows the generic to be considered therapeutically equivalent and substitutable for the brand-name extended-release formulation in U.S. pharmacy channels.

NYU Langone AI Tool Closes Radiology Training Gaps With 90% Accuracy

Image
NYU Langone AI Tool Closes Radiology Training Gaps With 90% Accuracy

New York – September 30, 2026 -- Researchers at NYU Langone Health have built an artificial intelligence system that tracks the daily case exposure of radiology residents and flags missing pathologies with more than 90 percent accuracy, according to a study published online in Academic Radiology.

AI system pinpoints training gaps that traditional case logs miss

The tool monitors which conditions residents encounter during clinical rotations and automatically identifies underexposed pathologies, then assigns supplemental teaching cases to close the gap. Study author Vinay Prabhu, an associate professor in NYU Grossman School of Medicine's Department of Radiology, said residents seeing 30 cases in a day typically encounter 29 routine exams and only one uncommon condition, leaving gaps in exposure to rarer diseases they will face throughout their careers.

LateralCare's Revenue Alai AI Platform Launches on Microsoft Marketplace

Image
LateralCare's Revenue Alai AI Platform Launches on Microsoft Marketplace

Dallas – September 30, 2026 -- LateralCare has made its flagship revenue cycle management platform, revenue alai, available on Microsoft Marketplace, giving healthcare organizations worldwide direct access to deploy the Agentic AI solution within existing Azure environments.

Microsoft Marketplace listing enables direct deployment within Azure ecosystems

Customers can now discover and deploy revenue alai through Microsoft Marketplace, the unified platform for cloud solutions, AI apps, and agents. The listing allows streamlined management and integration across Microsoft Azure and other Microsoft products, reducing procurement friction for healthcare systems already operating on Microsoft infrastructure.

ProgenyHealth Names Melanie Bella to Board, Alec DiDonato as COO

Image
ProgenyHealth Names Melanie Bella to Board, Alec DiDonato as COO

UNITED STATES – September 30, 2026 -- ProgenyHealth has appointed Melanie Bella to its Board of Managers and named Alec DiDonato as Chief Operating Officer, moves the maternity and NICU care management company says will support its national expansion.

Bella brings 25 years of Medicaid policy experience to the board

Bella, an Executive Advisor with Cressey & Company, previously chaired the Medicaid and CHIP Payment and Access Commission (MACPAC). She served as Executive Vice President of Policy and Duals Strategy at Cityblock Health, a value-based provider focused on Medicaid and dual-eligible populations, and was the first Director of the Medicare-Medicaid Coordination Office at the Centers for Medicare & Medicaid Services. She also served as Medicaid Director for the state of Indiana and holds an MBA from Harvard Business School and a bachelor's degree from DePauw University.

Forum Health Names Elizabeth Campbell CFO and Development Officer

Image
Forum Health Names Elizabeth Campbell CFO and Development Officer

Lisle, Ill. – – September 30, 2026 -- Forum Health, LLC has appointed Elizabeth Campbell as Chief Financial and Development Officer, a newly created role tasked with leading fundraising and acquisitions as the functional medicine network pursues rapid expansion.

Campbell joins after building and selling a 88-clinic orthodontic platform

Campbell co-founded myOrthos, LLC in 2019 and served as CEO, completing 37 acquisitions to build a platform of 88 clinics across 14 states before its 2025 sale to Smile Doctors, a portfolio company of TH Lee. She brings more than 20 years of experience spanning The Boston Consulting Group, private equity roles at SV Life Sciences Advisors and LLR Partners, and healthcare operating leadership.

Zifo: Fragmented CMC Data Creates 'Billion-Dollar Bottleneck' in Biopharma

Image
Zifo: Fragmented CMC Data Creates 'Billion-Dollar Bottleneck' in Biopharma

Cambridge, Mass. – September 30, 2026 -- Biopharma companies are losing time and money to a recurring pattern of disconnected experiments and manual data reconciliation that Zifo calls the 'DMTA doom loop,' according to a new position paper from the scientific informatics firm.

Zifo identifies a structural flaw in the Design-Make-Test-Analyse process

The paper, titled 'The Billion-Dollar Bottleneck: Why CMC Is Strangling the Biopharma Pipeline,' argues that the DMTA cycle used in chemistry, manufacturing and controls (CMC) work is forced into a rigid, linear execution model rather than adapting to what the science actually requires. Zifo says evidence in many CMC environments is scattered across scientific applications, instruments, spreadsheets, PDFs, batch records and individual expertise, forcing scientists to reconstruct experimental histories and decision reasoning before they can even begin new work.

Suvoda Unifies Clinical Trial Platform, Cuts RTSM Setup Time 80%

Image
Suvoda Unifies Clinical Trial Platform, Cuts RTSM Setup Time 80%

Conshohocken, Pa. – – September 30, 2026 -- Suvoda has released a unified clinical trial technology platform that merges its RTSM systems with Greenphire's financial management tools, cutting kickoff-to-UAT timelines by up to 80% through new agentic AI capabilities.

Agentic AI Slashes Setup Times Across RTSM and eCOA

Suvoda's new AI layer, starting with randomization and trial supply management (RTSM) and electronic clinical outcome assessment (eCOA), is delivering the 80% reduction in kickoff-to-UAT timelines. A conversational assistant called Sofia allows sponsors and sites to query data and execute permissioned actions across multiple languages, with every action logged for audit purposes while humans retain final sign-off authority.

Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Image
Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.

Resubmission follows April 2026 FDA alignment meeting

PFP filed the updated application after reaching agreement with the FDA during an April 2026 Type A meeting. The package includes an expanded dataset with additional patients and longer follow-up from the pivotal Phase 3 ALLELE study, which evaluates tabelecleucel in patients with EBV+ PTLD following hematopoietic cell transplant (HCT) or solid organ transplant (SOT).